Human Hepatitis B Immunoglobulin (IM)
Market
Human Hepatitis B Immunoglobulin (IM) Market
Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Human Hepatitis B Immunoglobulin (IM) Market Size and Growth
The Human Hepatitis B Immunoglobulin (IM) market is witnessing steady growth, driven by rising Hepatitis B prevalence and increased vaccination awareness. The market size is estimated to reach approximately USD 2 billion by 2027, fueled by advancements in biotechnology and a growing geriatric population requiring immunological support.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Baxter
◍ CSL
◍ Bayer
◍ Grifols
◍ Octapharma
◍ Shanghai RAAS
◍ Hualan Biological
◍ China Biologic
◍ Tiantan Biologic
◍ Shuanglin Bio-pharmacy
◍ Sichuan Yuanda Shuyang
◍ Boya Bio-pharmaceutical
◍ Shanghai Institute of Biological
The Human Hepatitis B Immunoglobulin (IM) market features key players like Baxter, CSL, and Grifols, focusing on product innovation and expanded distribution. Their R&D and strategic partnerships enhance market growth. Notable sales revenues include:
- Baxter: $13 billion
- CSL: $10 billion
- Grifols: $5 billion
Request Sample Report
Market Segmentation
By Application
◍ Positive Infants Born to Mothers With Hepatitis B Surface Antigen (HBsAg)
◍ Unexpected Crowd of Hepatitis B Infection
◍ Close Contacts of Patients with Hepatitis
B and Hepatitis B Virus Carriers
By
Product
◍ 100IU/Bottle Human Hepatitis B
Immunoglobulin (IM)
200IU/Bottle Human Hepatitis B
Immunoglobulin (IM)
400IU/Bottle Human Hepatitis B
Immunoglobulin (IM)
Market Growth
Request Sample Report
$ X Billion USD
